| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0161-813X(02)00065-7 |
| P698 | PubMed publication ID | 12428717 |
| P50 | author | John Q. Trojanowski | Q6253636 |
| P2093 | author name string | Virginia M Y Lee | |
| P2860 | cites work | Lewy Body Pathology in Alzheimer's Disease | Q22241400 |
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| A Drosophila model of Parkinson's disease | Q29617052 | ||
| Parkinson's disease. First of two parts | Q29620416 | ||
| beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease | Q33947152 | ||
| Studying human neurodegenerative diseases in flies and worms | Q34083380 | ||
| beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor | Q34099593 | ||
| Drosophila models of human neurodegenerative disease | Q34119278 | ||
| Synucleinopathies: clinical and pathological implications | Q34140347 | ||
| "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. | Q34148979 | ||
| Alpha-synuclein and the Lewy body disorders | Q34318165 | ||
| Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model | Q35747138 | ||
| Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease | Q43874109 | ||
| Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? | Q48389481 | ||
| Synucleins in synaptic plasticity and neurodegenerative disorders | Q62055336 | ||
| P433 | issue | 4-5 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 457-460 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | NeuroToxicology | Q15098069 |
| P1476 | title | Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses | |
| P478 | volume | 23 |
| Q53497967 | Abnormal serum concentrations of proteins in Parkinson's disease. |
| Q34278990 | Age-dependent synuclein pathology following traumatic brain injury in mice |
| Q36050277 | Alpha synuclein gene expression profile in the retina of vertebrates |
| Q37020862 | Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? |
| Q50879174 | CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. |
| Q37376117 | Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps |
| Q43256880 | Characterization of intrinsically disordered proteins with electrospray ionization mass spectrometry: conformational heterogeneity of alpha-synuclein |
| Q35191667 | Dementia with Lewy bodies: disease concept and genetics |
| Q35159808 | Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family |
| Q24307627 | Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies |
| Q48122029 | Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. |
| Q36616362 | Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease |
| Q33847578 | Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice |
| Q37691584 | Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans |
| Q37993988 | Nanopore analysis: An emerging technique for studying the folding and misfolding of proteins |
| Q28587583 | Neurons Expressing the Highest Levels of γ-Synuclein Are Unaffected by Targeted Inactivation of the Gene |
| Q37589209 | Opioid system in L-DOPA-induced dyskinesia |
| Q81562900 | Peripheral sensory neurons survive in the absence of alpha- and gamma-synucleins |
| Q35550987 | Protein Accumulation in Traumatic Brain Injury |
| Q35794541 | Proteomic approach to studying Parkinson's disease |
| Q48227693 | Proteomic identification of novel proteins in cortical lewy bodies |
| Q37800101 | Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies |
| Q38667942 | Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology |
| Q64943856 | Structural brain signature of cognitive decline in Parkinson's disease: DTI-based evidence from the LANDSCAPE study. |
| Q36577255 | The genetics of Parkinson disease: Implications for neurological care |
| Q36060421 | Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. |
Search more.